Results 11 to 20 of about 33,038 (222)

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

Castrate-resistant prostate cancer [PDF]

Current Opinion in Urology, 2013
Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.The development of ...
Song, Zhao, Evan Y, Yu
openaire   +2 more sources

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer

Pharmaceutics, 2021
Heat shock protein 27 (Hsp27) has an established role in tumor progression and chemo-resistance of castration-resistant prostate cancer (CRPC). Hsp27 protects eukaryotic translation initiation factor 4E (eIF4E) from degradation, thereby maintaining ...
Hajer Ziouziou, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, Palma Rocchi   +13 more
doaj   +1 more source

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Frontiers in Bioengineering and Biotechnology, 2022
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation.
Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen   +7 more
doaj   +1 more source

The biology of castration-resistant prostate cancer [PDF]

Current Problems in Cancer, 2015
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States. Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy
Fei, Lian, Nitya V, Sharma, Josue D, Moran, Carlos S, Moreno   +3 more
openaire   +2 more sources

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

Epiregulin expression and secretion is increased in castration-resistant prostate cancer

Frontiers in Oncology, 2023
IntroductionIn prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable.
Marc Wiesehöfer, Benedikt Bernhard Gereon Raczinski, Caroline Wiesehöfer, Jaroslaw Thomas Dankert, Elena Dilara Czyrnik, Martin Spahn, Martin Spahn, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Gunther Wennemuth   +11 more
doaj   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source